Table 2 List of the genes identified as differentially methylated and differentially expressed between cell lines that were also differentially expressed in the same way in primary seminoma and non-seminoma tumour samples22

From: Genome-wide methylation analysis identifies genes silenced in non-seminoma cell lines

A. Seminoma versus YST

Gene

Noor (2015)

Korkola et al.21

Palmer et al.22

EPCAM

561.2

0.4

0.4

TACSTD2

448.8

0.1

0.9

GGCT

120.4

1.0

1.5

F2RL1

106.1

0.9

0.8

TDRD12

84.4

8.5

8.0

FABP5

65.7

1.4

0.5

HSPA2

50.7

0.9

0.9

SOX17

48.7

0.8

0.6

RBMXL2

43.5

2.3

1.4

BASP1

42.0

0.8

1.3

DDX43

37.3

3.6

3.9

KLF4

29.9

5.9

7.2

LGALS3

28.1

0.8

1.6

ESRP2

27.7

0.3

0.5

CYB5R2

18.2

1.1

1.0

OXCT1

17.2

1.2

1.9

HIST1H4C

17.1

1.5

0.9

CLDN7

15.2

0.4

0.2

ALDH1A3

14.6

1.4

0.4

ECHDC3

14.5

0.9

1.8

TRIL

14.4

1.9

1.4

TMEM168

14.2

1.4

2.2

CXCL14

13.0

2.7

5.1

DSCR6

10.2

0.5

0.2

GPX7

9.6

1.0

1.0

FAM184A

9.4

0.4

0.5

ECHDC2

9.2

0.5

0.9

IER2

9.0

1.0

1.5

GUCA1A

7.5

1.8

1.2

LGALS8

7.4

0.6

0.9

ST14

6.7

0.7

0.5

MAPK13

6.3

0.5

0.8

LMO7

6.2

0.6

0.8

OVOL1

6.2

0.8

0.8

LY75

6.0

3.5

3.4

CYB5R1

5.6

1.0

1.3

GIPC2

5.6

0.6

0.8

EPS8L2

5.5

0.4

0.4

CST6

4.8

0.8

1.2

PKP3

4.7

0.4

0.3

ALX1

4.6

1.0

0.8

PARP12

4.3

3.9

2.6

BST1

4.3

1.5

1.5

CYP1B1

4.3

1.0

1.8

MNS1

3.6

1.0

1.0

SOX15

3.5

5.9

3.3

MTL5

3.5

0.8

0.8

MYD88

3.3

1.0

0.9

PRDM14

3.2

1.6

1.2

MEIS1

3.2

0.5

0.4

TNFRSF10C

3.1

0.9

1.0

TRIM25

3.1

1.0

0.9

PON3

3.0

1.6

4.9

PLXND1

3.0

1.0

0.9

RPRM

3.0

2.3

2.4

LTBP2

2.9

1.1

0.6

FUT1

2.8

1.1

1.0

SLC25A38

2.8

0.8

0.8

EPS8L1

2.6

0.8

0.7

ARPC1B

2.6

2.3

2.9

EDNRB

2.6

0.9

0.9

TEAD3

2.5

0.6

0.7

ACADL

2.5

1.1

0.9

TUBB6

2.5

0.9

0.6

ZMIZ1

2.4

1.6

1.1

ABHD14A

2.2

0.8

0.9

ELMO3

2.2

0.8

0.7

AMPD3

2.1

1.1

1.3

LRRFIP1

2.0

1.3

1.2

ZIC1

2.0

0.5

0.7

SH2D3A

1.6

1.0

1.0

NAAA

1.5

1.1

1.1

B. Seminoma versus EC

Gene

Noor (2015)

Korkola et al.21

TACSTD2

322.3

0.3

NUDT15

96.1

0.6

RBMXL2

52.8

1.6

HSPA2

35.6

0.6

DDX43

32.4

2.1

TDRD12

27.3

5.3

UCP2

24.6

0.8

MGLL

18.4

0.6

CRIP1

15.5

1.1

RPL39L

13.4

1.4

CHODL

12.1

1.2

MGMT

10.4

1.2

CYB5R2

8.5

0.9

CYP2R1

8.0

1.6

KRT7

7.6

0.6

PRKCH

6.0

0.6

MAPK13

6.0

0.8

CNTLN

5.8

1.2

CXCR7

5.7

0.4

CTSO

5.0

0.7

ST14

5.0

0.8

BST1

4.6

1.3

GREM2

4.5

0.9

DMRT1

4.4

5.1

SLC7A4

3.9

1.3

LTBP2

2.8

0.4

KDELR3

2.6

0.6

PON3

2.5

2.3

C. Seminoma versus teratoma

Gene

Noor (2015)

Korkola et al.21

TACSTD2

438.9

0.0

DDX43

43.7

4.5

RBMXL2

42.8

2.2

ME1

35.4

0.5

RBM12B

21.9

1.2

QPCT

20.4

0.6

PRKCH

14.7

0.7

CAT

12.9

0.4

GALNT3

12.7

0.2

ECHDC2

8.9

0.6

PKP3

6.7

0.6

ST14

6.7

0.5

GREM2

4.9

0.5

SOX15

3.8

5.3

EDNRB

3.1

0.4

PON3

2.9

1.6

CYP1B1

2.5

0.3

EPS8L1

2.5

0.8

SULT1A1

2.5

1.0

LPHN3

2.3

0.7

VAV1

2.3

1.1

TEAD3

2.2

0.7

ELMO3

2.0

0.8

  1. Abbreviations: EC, embryonal carcinoma; YST, yolk sac tumour.
  2. The ‘fold change’ column is the fold change in expression seen between the seminoma and non-seminoma cell lines in our study. The ‘Korkola fold change’ and ‘Palmer fold change’ are the difference in expression seen in primary tumours in the studies by Korkola et al.21 and Palmer et al.22 Only genes for which data were available in all data sets are shown. Genes where expression in seminoma cells is at least 1.5-fold greater than in the non-seminoma cells are in bold.